ZA957688B - Intracellular delivery of chemical agents to a specific cell type - Google Patents

Intracellular delivery of chemical agents to a specific cell type

Info

Publication number
ZA957688B
ZA957688B ZA957688A ZA957688A ZA957688B ZA 957688 B ZA957688 B ZA 957688B ZA 957688 A ZA957688 A ZA 957688A ZA 957688 A ZA957688 A ZA 957688A ZA 957688 B ZA957688 B ZA 957688B
Authority
ZA
South Africa
Prior art keywords
cell type
specific cell
chemical agents
intracellular delivery
intracellular
Prior art date
Application number
ZA957688A
Inventor
Ramesh K Prakash
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of ZA957688B publication Critical patent/ZA957688B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA957688A 1994-09-13 1995-09-13 Intracellular delivery of chemical agents to a specific cell type ZA957688B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30577094A 1994-09-13 1994-09-13

Publications (1)

Publication Number Publication Date
ZA957688B true ZA957688B (en) 1996-05-13

Family

ID=23182273

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA957688A ZA957688B (en) 1994-09-13 1995-09-13 Intracellular delivery of chemical agents to a specific cell type

Country Status (13)

Country Link
EP (1) EP0781139A1 (en)
JP (1) JPH10505835A (en)
KR (1) KR970705404A (en)
CN (1) CN1157570A (en)
AU (1) AU697469B2 (en)
BR (1) BR9508951A (en)
CA (1) CA2198361A1 (en)
CZ (1) CZ74797A3 (en)
HU (1) HUT77263A (en)
MX (1) MX9701860A (en)
PL (1) PL319100A1 (en)
WO (1) WO1996008263A1 (en)
ZA (1) ZA957688B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
WO1999007324A2 (en) * 1997-08-05 1999-02-18 Watson Pharmaceuticals, Inc. Conjugates targeted to the interleukin-2 receptor
CN1616665B (en) * 1997-11-19 2010-10-06 乔治敦大学 Targeted liposome gene delivery
DE19926154A1 (en) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Process for the preparation of an injectable pharmaceutical preparation
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
US12006339B2 (en) 2022-05-20 2024-06-11 Navidea Biopharmaceuticals, Inc. CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease

Also Published As

Publication number Publication date
CN1157570A (en) 1997-08-20
HUT77263A (en) 1998-03-02
KR970705404A (en) 1997-10-09
JPH10505835A (en) 1998-06-09
AU3550795A (en) 1996-03-29
PL319100A1 (en) 1997-07-21
CZ74797A3 (en) 1997-08-13
CA2198361A1 (en) 1996-03-21
EP0781139A1 (en) 1997-07-02
BR9508951A (en) 1999-04-06
MX9701860A (en) 1997-06-28
AU697469B2 (en) 1998-10-08
WO1996008263A1 (en) 1996-03-21

Similar Documents

Publication Publication Date Title
PL323995A1 (en) Stable reactants for use in manufacture of radiopharmaceutic agents
GB2270195B (en) Electrochemical cell
HU9600516D0 (en) Electro-chemical cell
AU6319698A (en) Liposomes containing active agents
HK1031474A1 (en) Battery pack
GB2302757B (en) Electrochemical cell
EP1015351A4 (en) Medicament dispensing cell
GB2324405B (en) A battery receptacle
ZA957688B (en) Intracellular delivery of chemical agents to a specific cell type
GB2270794B (en) Electrochemical cell
HUP0004799A3 (en) Use of electrolyte mixtures as sequestering agents
ZA985833B (en) p53 as a regulator of cell differentiation
GB9223766D0 (en) Improvements relating to batteries
GB9216393D0 (en) Electrochemical cell
GB9517757D0 (en) Battery container
GB2269265B (en) Electrochemical cell
AUPO265196A0 (en) Delivery of agents to a cell
EP0769211A4 (en) Small battery cell
PL323598A1 (en) Sorbic acid containing hydogels
GB2271667B (en) Battery cell
TW333187U (en) Improved structure of a pump type container
GB9220873D0 (en) Electrochemical cell
GB9219473D0 (en) Electrochemical cell
ZA941689B (en) Electrochemical cell
GB9212314D0 (en) Electrochemical cell